The U.K. will offer under-40s an alternative to the AstraZeneca Plc Covid-19 vaccine because of concerns about very rare blood clots that so far appear to be more common in younger people.
The decision, announced Friday, follows a recommendation by U.K. scientific advisory panel the Joint Committee on Vaccination and